Cartesian Therapeutics, Inc.: operating expenses
Operating expenses for Cartesian Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Cartesian Therapeutics, Inc. financial histories
What this measure means
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
Exact concept: us-gaap:OperatingExpenses. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 146,202,000 | USD | 2026-03-09 | 10-K · 0001453687-26-000064 |
| 2024-01-01 | 2024-12-31 | 82,810,000 | USD | 2026-03-09 | 10-K · 0001453687-26-000064 |
| 2023-01-01 | 2023-12-31 | 112,420,000 | USD | 2025-03-13 | 10-K · 0001453687-25-000060 |
| 2022-01-01 | 2022-12-31 | 96,239,000 | USD | 2024-03-07 | 10-K · 0001453687-24-000036 |
| 2021-01-01 | 2021-12-31 | 89,674,000 | USD | 2024-03-07 | 10-K · 0001453687-24-000036 |
| 2020-01-01 | 2020-12-31 | 73,418,000 | USD | 2023-03-02 | 10-K · 0001453687-23-000040 |
| 2019-01-01 | 2019-12-31 | 59,132,000 | USD | 2022-03-10 | 10-K · 0001453687-22-000051 |
| 2018-01-01 | 2018-12-31 | 65,925,000 | USD | 2021-03-12 | 10-K · 0001453687-21-000031 |
| 2017-01-01 | 2017-12-31 | 63,991,000 | USD | 2020-03-12 | 10-K · 0001453687-20-000028 |
| 2016-01-01 | 2016-12-31 | 42,753,000 | USD | 2019-03-15 | 10-K · 0001453687-19-000032 |
| 2015-01-01 | 2015-12-31 | 31,315,000 | USD | 2018-03-15 | 10-K · 0001453687-18-000012 |
| 2014-01-01 | 2014-12-31 | 18,439,000 | USD | 2017-03-28 | 10-K · 0001453687-17-000014 |
Related financial histories
- Cartesian Therapeutics, Inc.: total assets
- Cartesian Therapeutics, Inc.: total liabilities
- Cartesian Therapeutics, Inc.: stockholders equity
- Cartesian Therapeutics, Inc.: cash and cash equivalents
- Cartesian Therapeutics, Inc.: net income or loss
- Cartesian Therapeutics, Inc.: operating cash flow
- Cartesian Therapeutics, Inc.: capital expenditure payments
- Cartesian Therapeutics, Inc.: revenue
- Cartesian Therapeutics, Inc.: contract revenue excluding tax
- Cartesian Therapeutics, Inc.: financing cash flow
- Cartesian Therapeutics, Inc.: investing cash flow
- Cartesian Therapeutics, Inc.: retained earnings or deficit
- Cartesian Therapeutics, Inc.: basic weighted-average shares
- Cartesian Therapeutics, Inc.: diluted weighted-average shares
- Cartesian Therapeutics, Inc.: basic earnings per share
- Cartesian Therapeutics, Inc.: diluted earnings per share
- Cartesian Therapeutics, Inc.: income tax expense or benefit
- Cartesian Therapeutics, Inc.: net property, plant and equipment
- Cartesian Therapeutics, Inc.: share-based compensation expense
- Cartesian Therapeutics, Inc.: operating income or loss
- Cartesian Therapeutics, Inc.: current assets
- Cartesian Therapeutics, Inc.: interest expense
- Cartesian Therapeutics, Inc.: current liabilities
- Cartesian Therapeutics, Inc.: current accounts payable
- Cartesian Therapeutics, Inc.: goodwill carrying amount
- Cartesian Therapeutics, Inc.: net current accounts receivable
- Cartesian Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Cartesian Therapeutics, Inc. / CIK 0001453687
- Captured
- 2026-09-20T09:05:46.585Z
- SEC response SHA-256
1a706a4a3075779870f74e28a93e529a3aaa5f3c0c605cd926f6725bc8e3826e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001453687.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))